GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Authors :: Bethge, WA
Martus, P
Schmitt, M
Holtick, U
Subklewe, M
von Tresckow, B
Ayuk, F
Wagner-Drouet, EM
Wulf, G
Marks, R
Penack, O
Schnetzke, U
Koenecke, C
von Bonin, M
Stelljes, M
Glass, B
Baldus, CD
Vucinic, V
Mougiakakos, D
Topp, M
Fante, M
Schroers, R
Bayir, L
Borchmann, P
Buecklein, V
Hasenkamp, J
Hanoun, C
Thomas, S
Beelen, D
Lengerke, C
Kroeger, N
Dreger, P
Source :: Blood; 20240101, Issue: Preprints
Publication Year :: 2024
Abstract: CD19-directed chimeric antigen receptor (CAR) T cells have evolved as new standard-of-care (SOC) treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR-T cell therapies with the aim to explore risk factors associated with outcome.

Full Text Access

Tools